Where does Celgene Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Celgene Corporation ranks #1,345 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Celgene Corporation hold?

Celgene Corporation holds 313 US utility patents granted between 2015 and 2025, spanning 23 technology areas.

What is Celgene Corporation's Innovation Score?

Celgene Corporation has an Innovation Score of 54.5 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Celgene Corporation's patent grant rate increasing or decreasing?

Celgene Corporation's recent grant velocity is -17% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Celgene Corporation's patents?

Celgene Corporation's patents average 19.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Celgene Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Celgene Corporation

Q: What technology areas does Celgene Corporation focus on?

Celgene Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 228 patents. Grants appear in 23 CPC subclasses total.

USPTO PatentsView assignee record - 313 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Celgene ranks #1,345 of 49,997 tracked US assignees by granted-patent volume, with 313 patents across 23 technology areas.

#1,345
of 49,997 US assignees by volume: Top 8%
by Innovation Score (54.5/100): 19.4
avg claims per patent: -17%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R1345 · US Corporation #1,345 · 313 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-MID 313 grants
TOP-DECILE #1,345/49,997
PHOTO-FINISH Hisense USA
CPC-FOCUS A61P · 23 areas
INNOV-PAR 54.5/100
CLAIMS-RICH 19.4 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -17% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Hisense USA Corporation (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
CompoSecure · near

55
General Motors · near

55
Celgene · this assignee

54
Communications Test… · near

54
Ziehl-abegg SE · near

54
3D Lighting… · lowest

7

What this shows Celgene's Innovation Score is 54.5/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Celgene's grants concentrate

Celgene Corporation is a focused PatentsView assignee: 23 CPC subclasses with 72.8% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2017 (37 grants) versus a trough of 20 in 2024. By volume, Celgene sits between Manufacturing Resources International, Inc. and Global Tel*Link Corporation.

Celgene's three-year grant acceleration

From 2019–2021 to 2022–2024, Celgene Corporation moved from 86 to 78 grants (0.91x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #1,449. See the growth leaderboard.

Manufacturing Res…

315
Masonite

315
Furuno Electric

314
Sensor Technology

314
Hisense USA

313
Hong Kong Applied…

313
Sumitomo Osaka Ce…

313
Celgene ◀

313
Global Tel*Link

312

What this shows Celgene holds 313 patents at rank #1,345, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Celgene

By rank, the assignees closest to #1,345 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Celgene's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Celgene, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (54 here).

Ziehl-abegg SE 54 Communications Test Design, Inc. 54 General Motors LLC 55 CompoSecure, LLC 55

Similar claim depth

Nearest assignees by average claims per patent (19.4 here).

Universal City Studios LLC 19.4 avg AT&T Mobility II LLC 19.4 avg Afero, Inc. 19.4 avg Cardio Flow, Inc. 19.4 avg

Celgene's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Celgene Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	30	9.6%
2016	32	10.2%
2017	37	11.8%
2018	34	10.9%
2019	29	9.3%
2020	33	10.5%
2021	24	7.7%
2022	31	9.9%
2023	27	8.6%
2024	20	6.4%
2025partial year	16	5.1%

Which technologies does Celgene Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 228

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 211

C07D - Heterocyclic Compounds 144

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 53

C07K - Peptides 53

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 40

C07C - Acyclic OR Carbocyclic Compounds 30

Y02A - Technologies FOR Adaptation TO Climate Change 23

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 14

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 12

B65D - Containers FOR Storage OR Transport OF Articles OR Materials, e.g. Bags, Barrels, Bottles, Boxes, Cans, Cartons, Crates, Drums, Jars, Tanks, Hoppers, Forwarding CONTAINERS; Accessories, Closures, OR Fittings THEREFOR; Packaging ELEMENTS; Packages 8

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 6

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 5

Y02P - Climate Change Mitigation Technologies IN THE Production OR Processing OF Goods 4

Top 15 of 23 technology areas

Where it ranks

Overall rank by patents

#1,345

of 49,997 tracked assignees

Innovation Score

54.5 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Celgene Corporation's patent record in context - here's where to go next.

Celgene Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 72.8% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #1,345 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Celgene Corporation against Manufacturing Resources International, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 54.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.